We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

The Prevelence of HBB c.93-21 G-A in β Thalassemia Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05133388
Recruitment Status : Recruiting
First Posted : November 24, 2021
Last Update Posted : January 31, 2023
Information provided by (Responsible Party):
Amira Saber Hamed Ahmed, Assiut University

Brief Summary:
  • To design an amplification-refractory mutation system (ARMS) for the DNA diagnosis of the IVS I-110 (G>A) [HBB:c.93-21G˃A] mutation.
  • To detect the prevelence of the mutation among Assiut University Hospital patients.
  • Phenotype/genotype correlation of the mutation.

Condition or disease Intervention/treatment
Beta-Thalassemia Genetic: ARMS PCR

Detailed Description:
  • The β-thalassaemias result from over 300 gene mutations (Kurtoğlu A,et al 2016)
  • These mutations are regionally specific and the spectrum of mutations has been determined for most at-risk populations. The strategy for identifying β-thalassaemia mutations is usually based on knowledge of the common mutations in the ethnic group of the individual being screened (Old JM, 2007).

The β globin gene mutation [HBB:c.93-21G˃A] or IVS I-110 (G>A) is the most common β globin gene mutation in the Mediterranean region (Old JM, 2007). . There is no consensus about the % of the mutation among β thalassemic patients in Egypt [has been reported (25.8%) by El-Gawhary et al. 2007, (33.75%) by Soliman et al. 2010, (48%) by El-Shanshory et al. 2014, (22%) by Elmezayen et al. 2015 and (34%) by Elhalfawy et al. 2017].

According to the HbVar site, it represents 33% of the β globin gene mutations in the Egyptians. 28.5% according to Henderson S ,et al 2009 .

  • The mechanism of this mutation depends on formation of a new splicing site resulting in 80% abnormal spliced mRNA and 20% normal mRNA .
  • The molecular characterization of the globin gene mutation is necessary for definite diagnosis, genetic counseling, and in prenatal diagnosis.
  • The amplification-refractory mutation system (ARMS) is a simple method for detecting any mutation involving single base changes or small deletions.
  • The DNA is analyzed after amplification by PCR for Detection of point mutation IVS I-110 (G>A) by Using primer pairs that only amplify individual alleles.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 150 participants
Observational Model: Case-Control
Time Perspective: Retrospective
Official Title: The Prevelence of HBB c.93-21 G-A Gene Mutation in Suspected Cases of β Thalassemia in Assiut University Hospitals.
Actual Study Start Date : January 30, 2023
Estimated Primary Completion Date : June 2024
Estimated Study Completion Date : October 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Thalassemia

Intervention Details:
  • Genetic: ARMS PCR
    ARMS PCR using primer pairs that only amplify individual alleles

Primary Outcome Measures :
  1. Introduction of arms pcr in diagnosis . [ Time Frame: 2 years ]
    To introduce the ARMS PCR as a cheap and simple DNA diagnostic tool for any point mutation

  2. Database initation . [ Time Frame: 2 years ]
    Initiating database of haemoglobinopathesis by registering data.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Assiut University Hospitals patients

Inclusion Criteria:

  • β thalassemia (suspected & clinically diagnosed cases)

Exclusion Criteria:

  • Iron deficiency anaemia, anaemia of chronic disease, types of haemolytic anaemias other than thalassemia, other types of thalassemia and Hb variants.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05133388

Layout table for location contacts
Contact: Amira Saber 01063954423 amirasaberh@gmail.com
Contact: Mohamed Samir

Layout table for location information
Faculty of Medicine Assiut University Recruiting
Assiut, Egypt
Contact: Mohamed Samir    01015484723      
Sponsors and Collaborators
Assiut University
Layout table for investigator information
Study Director: Ola Afifi Assiut University

Layout table for additonal information
Responsible Party: Amira Saber Hamed Ahmed, ASHAhmed, Assiut University
ClinicalTrials.gov Identifier: NCT05133388    
Other Study ID Numbers: β thalassemia gene mutation
First Posted: November 24, 2021    Key Record Dates
Last Update Posted: January 31, 2023
Last Verified: January 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn